SCHEMBL4451716

SCHEMBL4451716

CC12CC3CC(C)(C1)CC(CC(N)=O)(C3)C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
GRIN1 Q05586 6/20 0.55
GRIN2A Q12879 6/20 0.55
GRIN2D O15399 5/20 0.55
GRIN3B O60391 5/20 0.55
GRIN2B Q13224 5/20 0.55
GRIN2C Q14957 5/20 0.55
GRIN3A Q8TCU5 5/20 0.55
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
SLC22A1 O15245 1/20 0.44
ESR1 P03372 1/20 0.44
ADRB3 P13945 1/20 0.44
ACHE P22303 1/20 0.44
OPRK1 P41145 1/20 0.44
MTOR P42345 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26217998 0.90 MEN1 (0.46) MEN1KMT2AGRIN1GRIN2AGRIN2D
SCHEMBL26218000 0.87 GRIN1 (0.50) MEN1KMT2AGRIN1GRIN2AGRIN2D
SCHEMBL1786642 0.83 MEN1 (0.53) MEN1KMT2AGRIN1GRIN2AGRIN2D
SCHEMBL12858118 0.82 MEN1 (0.49) MEN1KMT2AGRIN1GRIN2AGRIN2D
SCHEMBL4151999 0.81 MEN1 (0.52) MEN1KMT2AGRIN1GRIN2AGRIN2D
SCHEMBL5104994 0.81 MEN1 (0.51) MEN1KMT2AGRIN1GRIN2AGRIN2D
Hydrochloric Acid SCHEMBL7110650 0.80 MEN1 (0.59) MEN1KMT2AGRIN1GRIN2AGRIN2D
SCHEMBL5145929 0.80 PKM (0.50) MEN1KMT2AGRIN1GRIN2AGRIN2D
SCHEMBL25879662 0.80
SCHEMBL21747117 0.79 MEN1 (0.49) MEN1KMT2AGRIN1GRIN2AGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009057140-A2 IMPROVED PROCESS FOR MEMANTINE HYDROCHLORIDE MSN LABORATORIES LIMITED (IN) 2009-05-07 WO claimed
US-20230130425-A1 AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS PANORAMA RESEARCH, INC. 2023-04-27 US disclosed
US-20230130425-A1 AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS PANORAMA RESEARCH, INC. 2023-04-27 US disclosed
US-20200377444-A1 AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS PANORAMA RESEARCH, INC. 2020-12-03 US disclosed
CN-101389594-B Process for the preparation of adamantanamines HEXAL AG 2013-06-12 CN disclosed
CN-101389594-A Process for the preparation of adamantanamines HEXAL AG (DE) 2009-03-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377444-A1 AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS NLN, SLC1A2, AANAT MEN1 1333/4885KMT2A 1928/4885GRIN1 98/4885
US-20230130425-A1 AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS NLN, SLC1A2, AANAT MEN1 1333/4885KMT2A 1928/4885GRIN1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.